Oruka Therapeutics (ORKA) Net Equity Issued and Repurchased (2010 - 2026)

Oruka Therapeutics' Net Equity Issued and Repurchased history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was -$617000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $671000.0, up 1142.59% from the prior year.
• Net Equity Issued and Repurchased improved to $1.7 million in Q1 2026 per ORKA's latest filing, from $562000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $3.0 million in Q1 2024 and bottomed at -$2.9 million in Q4 2024.
• The 3-year median for Net Equity Issued and Repurchased is $562000.0 (2025), against an average of $462800.0.
• Biggest YoY gain for Net Equity Issued and Repurchased was 119.53% in 2025; the steepest drop was 119.53% in 2025.
• Year by year, Net Equity Issued and Repurchased stood at -$2.9 million in 2024, then soared by 119.53% to $562000.0 in 2025, then surged by 202.14% to $1.7 million in 2026.
• Per Business Quant, the three latest ORKA Net Equity Issued and Repurchased figures stand at $1.7 million (Q1 2026), $562000.0 (Q4 2025), and -$2.9 million (Q4 2024).